DANIEL J BOOSER's research topics

DANIEL J BOOSER

Concepts (361)

Back to Profile

Concepts are derived automatically from a person's publications.

The timeline below shows the dates (blue tick marks) of publications associated with DANIEL J BOOSER's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that DANIEL J BOOSER has written about over time.

Antibiotics, Antineoplastic, 6 publications between 1994 and 2002, average publication date December 1997. Neutropenia, 9 publications between 1984 and 2023, average publication date July 2000. Antineoplastic Agents, Phytogenic, 14 publications between 1998 and 2003, average publication date August 2001. Lacrimal Duct Obstruction, 3 publications between 2001 and 2002, average publication date December 2001. Doxorubicin, 33 publications between 1984 and 2024, average publication date January 2002. Cyclophosphamide, 22 publications between 1984 and 2024, average publication date October 2002. Fluorouracil, 20 publications between 1995 and 2012, average publication date June 2003. Middle Aged, 81 publications between 1984 and 2024, average publication date August 2003. Paclitaxel, 22 publications between 1993 and 2024, average publication date October 2003. Antineoplastic Combined Chemotherapy Protocols, 48 publications between 1984 and 2024, average publication date May 2004. Neoplasm Metastasis, 22 publications between 1993 and 2019, average publication date November 2004. Breast Neoplasms, 79 publications between 1992 and 2019, average publication date January 2005. Taxoids, 15 publications between 1998 and 2013, average publication date February 2006. Drug Resistance, Neoplasm, 11 publications between 1998 and 2024, average publication date March 2007. Neoadjuvant Therapy, 12 publications between 2000 and 2024, average publication date April 2008. Receptor, ErbB-2, 10 publications between 2002 and 2019, average publication date October 2008. Sirolimus, 4 publications between 2011 and 2015, average publication date June 2012. Receptor, Platelet-Derived Growth Factor beta, 2 publications between 2008 and 2018, average publication date August 2013. Triple Negative Breast Neoplasms, 2 publications between 2023 and 2024, average publication date January 2024.

Antibiotics, Antineoplastic
Neutropenia
Antineoplastic Agents, Phytogenic
Lacrimal Duct Obstruction
Doxorubicin
Cyclophosphamide
Fluorouracil
Middle Aged
Paclitaxel
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Metastasis
Breast Neoplasms
Taxoids
Drug Resistance, Neoplasm
Neoadjuvant Therapy
Receptor, ErbB-2
Sirolimus
Receptor, Platelet-Derived Growth Factor beta
Triple Negative Breast Neoplasms

To see the data from this visualization as text, click here.

Name	Number of Publications	First Publication Year	Most Recent Publication Year	Average Publication Date
Antibiotics, Antineoplastic	6	1994	2002	December 1997
Neutropenia	9	1984	2023	July 2000
Antineoplastic Agents, Phytogenic	14	1998	2003	August 2001
Lacrimal Duct Obstruction	3	2001	2002	December 2001
Doxorubicin	33	1984	2024	January 2002
Cyclophosphamide	22	1984	2024	October 2002
Fluorouracil	20	1995	2012	June 2003
Middle Aged	81	1984	2024	August 2003
Paclitaxel	22	1993	2024	October 2003
Antineoplastic Combined Chemotherapy Protocols	48	1984	2024	May 2004
Neoplasm Metastasis	22	1993	2019	November 2004
Breast Neoplasms	79	1992	2019	January 2005
Taxoids	15	1998	2013	February 2006
Drug Resistance, Neoplasm	11	1998	2024	March 2007
Neoadjuvant Therapy	12	2000	2024	April 2008
Receptor, ErbB-2	10	2002	2019	October 2008
Sirolimus	4	2011	2015	June 2012
Receptor, Platelet-Derived Growth Factor beta	2	2008	2018	August 2013
Triple Negative Breast Neoplasms	2	2023	2024	January 2024

BOOSER's Networks

Click the

Explore

buttons for more information and interactive visualizations!

Concepts (361)

Explore

Co-Authors (78)

Explore

Similar People (60)

Explore

Same Department

Explore